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LIVER INJURY/REGENERATION
Human Keratin 8 Variants Promote Mouse
Acetaminophen Hepatotoxicity Coupled With c-Jun
Amino-Terminal Kinase Activation and Protein
Adduct Formation
Nurdan Guldiken,1,2 Qin Zhou,3 Ozlem Kucukoglu,2 Melanie Rehm,2 Kateryna Levada,1 Annika Gross,1
Raymond Kwan,4 Laura P. James,5 Christian Trautwein,1 M. Bishr Omary,4 and Pavel Strnad1,2
Keratins 8 and 18 (K8/K18) are the intermediate filaments proteins of simple-type
digestive epithelia and provide important cytoprotective function. K8/K18 variants pre-
dispose humans to chronic liver disease progression and poor outcomes in acute acet-
aminophen (APAP)-related liver failure. Given that K8 G62C and R341H/R341C are
common K8 variants in European and North American populations, we studied their
biological significance using transgenic mice. Mice that overexpress the human K8 var-
iants, R341H or R341C, were generated and used together with previously described
mice that overexpress wild-type K8 or K8 G62C. Mice were injected with 600 mg/kg of
APAP or underwent bile duct ligation (BDL). Livers were evaluated by microarray anal-
ysis, quantitative real-time polymerase chain reaction, immunoblotting, histological and
immunological staining, and biochemical assays. Under basal conditions, the K8 G62C/
R341H/R341C variant-expressing mice did not show an obvious liver phenotype or
altered keratin filament distribution, whereas K8 G62C/R341C animals had aberrant
disulphide cross-linked keratins. Animals carrying the K8 variants displayed limited
gene expression changes, but had lower nicotinamide N-methyl transferase (NNMT) lev-
els and were predisposed to APAP-induced hepatotoxicity. NNMT represents a novel
K8/K18-associated protein that becomes up-regulated after K8/K18 transfection. The
more pronounced liver damage was accompanied by increased and prolonged JNK acti-
vation; elevated APAP protein adducts; K8 hyperphosphorylation at S74/S432 with
enhanced keratin solubility; and prominent pericentral keratin network disruption. No
differences in APAP serum levels, glutathione, or adenosine triphosphate levels were
noted. BDL resulted in similar liver injury and biliary fibrosis in all mouse genotypes.
Conclusion: Expression of human K8 variants G62C, R341H, or R341C in mice predis-
poses to acute APAP hepatotoxicity, thereby providing direct evidence for the impor-
tance of these variants in human acute liver failure. (HEPATOLOGY 2015;62:876-886)
D
rug-induced liver injury represents a significant
health problem given that it constitutes the
major cause of acute liver failure (ALF) in the
developed world and the major adverse event leading to
termination of clinical drug development program.1,2
Acetaminophen (APAP) toxicity is the predominant
cause of drug-induced ALF and accounts for approxi-
mately 50% of ALF cases in the United States and the
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UK.1 APAP is metabolized primarily through glucuroni-
dation and sulfation whereas 5%-15% is oxidized
through the cytochrome P450 system, thereby leading
to production of N-acetyl-p-benzoquinone imine
(NAPQI).
At therapeutic APAP doses, NAPQI is detoxified by
conjugation with sulfhydryl groups that are donated by
glutathione. However, after higher exposure, glutathione
becomes depleted and NAPQI binds covalently to hepa-
tocellular proteins. This proteotoxic stress leads to acti-
vation of stress kinases, such as c-Jun-N-terminal kinase
(JNK) and development of liver injury.3,4 While APAP
is generally considered safe at therapeutic doses, nearly
30% of patients display an increase in alanine amino-
transferase (ALT) levels after only 5 days of ingestion,
thereby suggesting genetic differences in APAP suscepti-
bility.3,5 Whereas genes responsible for APAP metabo-
lism are the most obvious candidates, keratin
polypeptides 8 and 18 (K8/K18) are also candidate
modifier genes that influence the outcome of APAP-
induced ALF.3,6 In particular, a large study suggested
that the presence of biologically significant K8 variants
predisposes their carriers to an adverse outcome of
APAP-induced ALF.6
Keratins represent the largest subgroup of the inter-
mediate filament protein family and are expressed in all
epithelia cells and skin appendages.7,8 Keratins are sub-
divided into type I (K9-K40) and II (K1-K8, K71-
K86), and both types assemble in an equimolar ratio to
form obligate noncovalent heteropolymers.7,8 Keratins
function as cytoprotective proteins and their mutations
are associated with at least 40 different human diseases.9
Their heteropolymeric nature and epithelial cell-specific
expression are reflected by the presence of cell-type-
selective displays of keratin repertoires and pairings.7,10
For example, K8/K18 are the major keratins of single-
layered or glandular epithelia whereas the pairs, K1/K10
and K5/K14, are expressed in suprabasal and basal epi-
dermal cells, respectively.7,10
Adult hepatocytes are unique in that they express
only K8/K18, whereas most other epithelial cells display
a more complex keratin pattern,10,11 which explains
why mutations in K8/K18 result in a predominantly
hepatic phenotype. Animals that lack K8/K18 or overex-
press the keratin filament disruptor, K18 R90C, develop
mild liver injury under basal conditions, but are mark-
edly predisposed to injury in a wide range of experimen-
tal liver injury models.10-12 These animal findings led to
human association studies that identified K8/K18 var-
iants as risk factors for liver fibrosis and end-stage liver
disease progression in several chronic liver disorders,
such as hepatitis C infection and primary biliary cirrho-
sis (PBC).6,10 Moreover, K8 variants predisposed their
carriers to an adverse acute liver injury outcome, as
observed in patients with ALF.6 K8 G62C and K8
R341H are the most common heterozygous K8/K18
variants in Caucasians and are observed in 3.2% and
1.5% of this population, respectively, whereas K8
R341C is rare, but offers important insights into disease
pathology owing to the toxicity of cysteines in simple
epithelial keratins.6,12-14
Despite the large body of evidence linking K8/K18
variants to human liver disease, little is known regarding
their underlying pathomechanisms. In vitro and in vivo
cell culture and animal data, respectively, suggest that
K8/K18 variants compromise stress-induced K8/K18
hyperphosphorylation and impair keratin network reor-
ganization under these conditions.10,11,15,16 Similarly,
livers of mice overexpressing K8 G62C stimulated with
Fas ligand manifest markedly decreased K8 S74 phos-
phorylation and shunting of phosphorylation to other
stress-activated kinase substrates with consequent
enhanced liver injury, as compared with mice that over-
express WT K8.17
To determine what hepatic stresses are modulated by
the presence of K8/K18 variants, and to study the under-
lying mechanisms, we generated mice that overexpress
human K8 R341H or R341C and (together with the
previously described K8 G62C mice) subjected them to
acute APAP injury or chronic biliary injury induced by
bile duct ligation (BDL). Our data demonstrate that sev-
eral naturally occurring K8 variants predispose to APAP
toxicity through JNK activation, with increased K8
phosphorylation at S74 and S432, enhanced K8/K18
solubility and filament network disruption, as well as
more-prominent formation of APAP-cysteine adducts.
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Materials and Methods
Mouse Experiments. Transgenic (Tg) mice that
overexpress human (h) K8 R341H/R341C were gener-
ated as previously described for the mice that overex-
press human K8 G62C.17 First, a BamHI-SalI fragment
from the wild-type (WT) 12-kilobase genomic
sequence18 was subcloned into pcDNA3.1 vector. The
Arg-to-His/Cys mutation (CGT->CAT/TGT) was
introduced using a Quickchange site-directed mutagene-
sis kit (Stratagene, La Jolla, CA) and confirmed by
sequencing. The mutated K8 fragment was comple-
mented with a K8 segment excised from the original
clone. The constructs were injected into pronuclei of
fertilized FVB/n mouse eggs. The offspring was geno-
typed with primers specific for hK8, as described previ-
ously17 (Supporting Table 1) and maintained on an
FVB/n background. To confirm the presence of the
described K8 variants, sequencing of K8 exons 1 and 6
was performed (Supporting Fig. 1; Supporting Table 1).
The strains used in this study are termed as WT K8, K8
G62C, and K8 R341H/C mice to highlight the K8 vari-
ant they overexpress. Notably, the sequence identity of
mouse and human K8 is 88%, and the K8 G62 and
R341 residues are highly conserved across species. In
addition, we analyzed the previously described K18-null
mice19 and their non-Tg littermates (both are in an
FVB/N background).
To study APAP hepatotoxicity, 2-month-old mice
were fasted overnight, injected intraperitoneally with
APAP (600 mg/kg mouse weight; Fagron GmbH&Co
KG, Barsb€uttel, Germany) and sacrificed 4 or 18 hours
later by CO2 inhalation followed by blood collection. In
another set of experiments, BDL was performed in 3-
month-old animals anesthetized with isoflurane. After
midline laparotomy, the bile duct was ligated with 2-0
or 5-0 nonabsorbable surgical silk (Perma-hand; Ethi-
con, Somerville, NJ) and animals were followed for 21
days. Dissected livers were weighed and pieces were fixed
using 10% formaldehyde (histological staining), snap
frozen in liquid nitrogen (biochemical analysis), or
placed in RNAlater stabilization reagent (Ambion, Life
Technologies GmbH, Darmstadt, Germany). Serum
parameters were measured in the Clinical Chemistry
Department (University Hospital Ulm, Ulm, Ger-
many). Animal experiments were approved by the insti-
tutional animal care committees of the participating
centers. For details on staining, messenger RNA
(mRNA) isolation, real-time polymerase chain reaction
(RT-PCR), microarray analysis, biochemical methods,
cell transfection experiments, and statistical evaluation,
see the Supporting Methods section.
Results
To characterize the Tg mouse lines generated in this
study, we first quantified their keratin expression levels.
All Tg lines displayed moderate hK8 mRNA overexpres-
sion, with levels being K8 R341C>WT K8K8
G62CK8 R341H whereas no changes in mouse (m)
K8 mRNA were observed (Fig. 1A,B). Consistent with a
previous report,20 K8 overexpression up-regulated K18
mRNA levels, and, consequently, the highest K18 mRNA
was observed in WT K8 and K8 R341C mice (Fig. 1C).
hK8 and K18 protein levels mirrored the mRNA results,
whereas hK8 overexpression led to compensatory down-
regulation of mK8 (Fig. 1D,E), which is in line with pre-
vious reports of WT K8 overexpression.17,20
Given that introduction of cysteine residues into oth-
erwise cysteine-free hK8 may lead to formation of disul-
phide bridges,14,17 we analyzed K8/K18 species under
Fig. 1. Keratin 8 G62C/R341C variants promote keratin crosslinking
under basal conditions. Human (h) K8 (A) and mouse (m) K18/K8 (B
and C) mRNA and protein levels (D) were quantified by RT-PCR and
immunoblotting, respectively. (E) To directly visualize proteins, a high
salt extraction (HSE) with SYPRO ruby staining was performed from
non-Tg livers (FVB/N) as well as tissues overexpressing WT K8 or the
highlighted K8 variants. (F) To test the formation of disulfide bridges,
livers were homogenized under nonreducing conditions. After longer
exposure (upper panel), a significant amount of cross-linked hK8 was
detected in G62C and R341C livers and the cross-links went away
under reducing conditions (not shown). L7 (mouse ribosomal protein)
and actin were used as an internal/loading control for quantitative RT-
PCR and immunoblotting, respectively. At least 4 mice were analyzed
per genotype and the results are expressed as mean 6 standard error
of the mean. *P < 0.05; **P < 0.01; ***P < 0.001.
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nonreducing conditions. High-molecular-weight K8/
K18 species were easily observed in K8 G62C/R341C
micebut not in WT K8 and K8 R341H animals (Fig.
1F). All Tg mouse lines displayed a normal-appearing
K8/K18 filament network in the liver under basal condi-
tions; however, this network was more dense in the K8
R341C livers that carry the highest K8 expression levels
(Fig. 2; Supporting Fig. 2).
hK8 overexpression did not cause any lethality,
growth defect, or organ malfunction (not shown).
Under basal conditions, all Tg lines had normal-
appearing liver architecture and normal ALT levels (Fig.
3Aa-d,B). To further characterize the consequences of
the presence of K8 variants, we performed microarray
analysis that revealed modest changes among the geno-
types (Fig. 4 and Supporting Fig. 3; Supporting Tables 2
and 3). Notably, nicotinamide N-methyltransferase
(NNMT) was the only mRNA that was significantly
altered in all mouse lines harboring K8 variants (Fig.
4D). Interestingly, K8/K18 transfection into NIH-3T3
cells resulted in NNMT up-regulation, whereas K18-
null livers and their normal controls displayed similar
NNMT expression levels (Supporting Fig. 4). In addi-
tion, immunoprecipitation (IP) experiments in two dif-
ferent hepatocellular cell lines (HepG2 and Huh7)
showed coimmunoprecipitation of NNMT with K8/
K18 (Fig. 4E-F).
Given that NNMT represents a prominent N-
methylating enzyme involved in xenobiotic metabo-
lism21 and given that patients carrying K8 variants are
predisposed to APAP-induced ALF,6 we examined the
susceptibility of our animals to this form of injury. Four
hours post-APAP administration, mild hepatocellular
swelling and elevated ALT levels were noted; however,
both parameters did not differ significantly among the
genotypes (Fig. 3Ae-h,C). More-prominent hepatocyte
swelling and centrolobular necrosis became apparent 18
hours post-APAP challenge, and both liver damage and
ALT levels were significantly higher in mice with K8
variants, compared to WT K8 mice (Fig. 3Ai-l,D,E).
On the other hand, no obvious differences in suscepti-
bility to APAP injury were noted between WT K8 mice
and their non-TG littermates (not shown) or between
WTand K18 KO animals (Supporting Fig. 5).
To delineate the mechanisms leading to increased
APAP hepatotoxicity in mice with K8 variants, we
examined APAP metabolism. Neither APAP plasma lev-
els (4 hours post-APAP administration) nor expression
of APAP-metabolizing enzymes differed significantly
among the Tg mouse lines (Supporting Figs. 6 and 7).
Notably, 18 hours post-APAP administration, APAP
plasma levels were below the detection limit in all
genotypes (not shown). Next, we evaluated glutathione
content because its depletion represents a crucial event
in APAP toxicity.3,4 Under basal conditions, all animals
displayed similar total glutathione levels and oxidized/
reduced glutathione GSSG/GSH ratios (Supporting Fig.
8A,B). As expected, APAP treatment resulted in
depletion of total glutathione and an increase in the
GSSG/GSH ratio, but both parameters were similar
across genotypes (Supporting Fig. 8A,B).
APAP administration also leads to hepatic inflamma-
tion with increased plasma interleukin-6 and tumor
necrosis factor alpha (TNF-a) levels as well as adenosine
triphosphate (ATP) depletion.3,4 However, comparable
cytokine and ATP levels were observed in all mouse lines
pre- and post-APAP exposure (Supporting Fig. 8C-E).
In addition, apoptosis levels post-APAP exposure were
negligible (as expected4) and did not differ significantly
among genotypes (Supporting Fig. 8F).
Fig. 2. Overexpression of K8 variants does not alter the morphology
of keratin network under basal condition. Livers from Tg mice overex-
pressing WT human (h) keratin 8 (WT K8), hK8 G62C, or K8 R341C/
R341H variant, and from non-Tg animals (FVB/N) were stained with
an antibody recognizing both mouse and human K8/K18 (antibody
8592) or an antibody specific for hK8 (M20). Only nonspecific, weak
hK8 staining was observed in FVB/N animals (A) whereas K8 R341H
livers displayed a somewhat patchy hK8 distribution (I). Scale bar 5
100 lm.
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Fig. 3. K8 G62C and R341C/H variants promote APAP-induced liver injury. Mice overexpressing WT K8 or the K8 G62C/R341H/R341C variant
were injected with 600 mg/kg of APAP intraperitoneally (i.p.) and sacrificed after 4 and 18 hours, respectively. (A) H&E staining detected no
obvious liver injury in untreated animals (a-d), whereas only a mild hepatocellular swelling that did not differ among the genotypes was noted 4
hours post-APAP exposure (e-h). Distinct hepatocyte swelling and centrolobular necrosis became apparent 18 hours post-APAP challenge (i-l)
and the liver damage was more prominent in mice carrying K8 variants, as compared to WT K8, as quantified by morphometric analysis (E).
Largely normal ALT levels were observed in untreated mice (B) whereas animals exposed to APAP for 4 hours displayed uniformly elevated ALTs
that did not differ among genotypes (C). (D) Eighteen hours post-APAP administration, mice carrying K8 variants displayed significantly higher
ALT levels than WT K8 animals (medians: WT K8: 221 U/L; K8 G62C: 554 U/L; K8 R341C: 485 U/L; K8 R341H: 2,165 U/L). Box plots display
median with first and third percentile, whereas whiskers indicate smallest and largest nonoutlier observations. For APAP experiments, at least 10
mice were analyzed per genotype. In (E), the results are expressed as mean 6 standard error of the mean. Scale bar 5 100 lm.*P < 0.05;
**P < 0.01; ***P < 0.001. Abbreviation: H&E, hematoxylin and eosin.
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We analyzed the levels of total JNK1 and JNK2, the
active phosphorylated JNK (pJNK) and the APAP pro-
tein adducts given their prominent role in APAP hepa-
totoxicity.3,4 Four hours post-APAP exposure, K8
G62C/R341C mice displayed moderately increased
JNK1 and robustly elevated pJNK, but not JNK2 levels
(Fig. 5A). No differences were noted under basal condi-
tions (not shown). Furthermore, 18 hours, but not 4
hours post-APAP administration, APAP protein adducts
were significantly higher in K8 G62C/K8 R341C mice,
compared to WT K8s (Fig. 5B).
To better understand the role of K8 variants in APAP
hepatotoxicity, we evaluated APAP-induced K8/K18
changes. Eighteen hours post-APAP exposure, both K8
G62C and K8 R341C mice displayed significant K8
hyperphosphorylation at S74 and S432. As a likely
mechanism, pJNK levels were increased in these ani-
mals, whereas no differences were noted in phospho-
p38 kinase (Fig. 5C). Consistent with keratin hyper-
phosphorylation, mice carrying K8 variants displayed
increased K8 solubility that was confirmed by densito-
metric quantification (Fig. 5D,E16), whereas no obvious
differences in solubility were noted under basal condi-
tions (not shown). Immunofluorescence (IF) staining
showed that K8 hyperphosphorylation was most promi-
nent in pericentral areas, where it resulted in keratin net-
work disruption (Fig. 6A and Supporting Fig. 9). Both
keratin hyperphosphorylation and keratin network
Fig. 4. NNMT represents a novel K8/K18-associated protein that was discovered by microarray analysis. (A) List of genes that are most signifi-
cantly altered in untreated mice carrying K8 G62C/R341H variant versus animals overexpressing WT K8, as determined by expression profiling
analysis. RT-PCR analysis (B-D) demonstrated that the drug metabolism-associated gene, NNMT, is the only gene that is similarly reduced in all
mouse lines carrying K8 variants. L7 (mouse ribosomal protein) gene was used as an internal control. At least 4 mice were analyzed per geno-
type and results are expressed as mean 6 standard error of the mean. *P < 0.05; **P < 0.01. (E and F) To immunoprecipitate K8/K18, 1%
NP-40 lysates from HepG2 or Huh7 cells were incubated with protein G dynabeads conjugated with the anti-human K18 antibody, L2A1 (IP).
Nonconjugated beads were used as a control. The lysates before incubation with the antibody were analyzed as an input. (E) Coomassie staining
confirms the specificity of the IP, whereas immunoblotting for the indicated antigens (F) identifies NNMT as a K8/K18-associated protein. Abbrevi-
ation: n.s., not significant.
HEPATOLOGY, Vol. 62, No. 3, 2015 GULDIKEN ET AL. 881
disruption were more prominent in K8 G62C/R341C
mice, compared to WT K8 animals (Fig. 6 and Support-
ing Fig. 9).
Given the reported association of K8/K18 variants
with liver disease development in patients with PBC,22
we also analyzed the role of K8 variants in BDL-
induced chronic cholestatic liver injury. All animals
exhibited markedly elevated bilirubin, ALT, and alkaline
phosphatase (ALP) 21 days post-BDL, but no differen-
ces were noted among the genotypes (Fig. 7B-D). More-
over, the overall extent of liver injury and liver fibrosis as
well as collagen mRNA levels were similar in all experi-
mental groups (Fig. 7A,E and Supporting Fig. 10).
In summary, our data show that the presence of K8
variants predisposes to APAP hepatotoxicity, but not to
cholestatic liver injury, in association with increased
JNK activation, more prominent formation of protein
adducts, and alterations in the K8/K18 system (Fig. 8).
Discussion
Given the established link between the presence of
K8/K18 variants and the development of several human
liver diseases,11,12 we generated Tg animals carrying
common human K8 variants observed in Caucasians
from the United States and Europe in order to delineate
Fig. 5. Mice carrying K8 variants display activated JNK signaling, stronger formation of APAP protein adducts, K8 hyperphosphorylation, and
increased K8 solubility. (A and C) Total liver lysates from APAP-exposed mice carrying either WT K8 or K8 variants were subjected to immunoblot-
ting using antibodies to the indicated antigens. (B) Formation of APAP protein adducts was analyzed 4 and 18 hours post-APAP administration
by high-performance liquid chromatography with electrochemical detection (expressed as nmol of cysteine adducts per mg of protein). (D and E)
Keratin solubility in 1% Triton X-containing buffer was assessed by immunoblotting and the ratio of soluble (upper panel) and insoluble (lower
panel) K8 was quantified by densitometric analysis. K8 solubility in WT K8 mice was arbitrarily set as 1 and levels in the other genotypes repre-
sent a ratio. Actin was used as a loading control. At least 4 mice per genotype were analyzed and the results are expressed as mean 6 stand-
ard error of the mean. *P < 0.05; **P < 0.01; ***P < 0.001. Abbreviations: i.p., intraperitoneally; p, phospho.
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the biological significance of the variants. Under basal
conditions, K8 R341H/R341C mice did not display
hepatic alterations or changes in the K8/K18 filament
network, which is similar to previous findings in K8
G62C mice (Fig. 8). In contrast, keratin filament dis-
ruption under basal conditions, as occurs in K18 R90C
livers, results in hepatocyte fragility and spontaneous
mild hepatitis.12 The effect of the K18 R90C mutation
is not surprising given that it is located in the most
conserved regions of K18 mimicking the severely dis-
ruptive keratin mutations found in epidermal genoder-
matoses,23 whereas K8 G62/R341, though highly
conserved residues, are situated in less-conserved
domains.11,12 One potential caveat of our models is the
expression of the human keratins in the background of
endogenous mouse keratins and the potential differences
in keratin expression levels. However, human K8
appears to integrate normally into the endogenous
mouse keratin filament network, which is not surprising
given the 88% identity of mouse and human K8.
Post-APAP exposure, all mouse lines carrying K8 var-
iants exhibited increased hepatotoxicity (Fig. 8), which
supports the human findings that suggested a K8/K18
mutation-based predisposition toward adverse outcome
of APAP-induced ALF.6 As a potential underlying mech-
anism, the presence of K8 variants resulted in a more
prominent JNK activation that is instrumental in
APAP-induced cell death.24 These findings are in line
with previous reports that linked activation of JNK
pathway to disturbances in the keratin system. For
example, prolonged JNK phosphorylation was observed
in keratinocyte cell lines carrying mutations in the
Fig. 6. Mice carrying K8
variants display pericentral
keratin network disruption
and K8 hyperphosphorylation
post-APAP exposure. Mice
overexpressing WT K8 or K8
variants were treated with
APAP for 18 hours and the
resulting liver sections were
subjected to IF staining with
K8/K18 antibody alone (a-c,
g-i) or to a combination of
K8/K18 (green) and the
depicted phospho-specific
(p) K8 antibody (red; d-f, j-
l). Note that animals carry-
ing K8 variants display a
more pronounced pericentral
K8 hyperphosphorylation
and keratin network disrup-
tion (the latter is highlighted
by arrows), as confirmed by
morphometrical quantifica-
tion (B). At least 3 mice
were analyzed per genotype
and the results are
expressed as mean 6
standard error of the mean.
Scale bar 5 50 lm. *P <
0.05; **P < 0.01.
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Fig. 7. Presence of K8 variants does
not affect development of BDL-induced
liver fibrosis. (A-C) Three weeks post-
BDL, mice displayed significantly ele-
vated bilirubin, ALT, and ALP levels;
however, no significant differences were
noted among genotypes. Furthermore,
in all untreated animals, bilirubin, ALT,
and ALP levels were within normal
range. (E) Extent of liver fibrosis in
untreated animals (basal) as well as
mice subjected to BDL for 3 weeks
was evaluated by Picro Sirius Red
staining. Note that animals overex-
pressing WT K8 or the depicted K8 var-
iants display a similar amount of liver
scarring and similar hepatic collagen
mRNA levels, as determined by quanti-
tative RT-PCR (D). L7 (mouse ribosomal
protein) gene was used as an internal
control. At least 4 mice were analyzed
per genotype and results are expressed
as mean 6 standard error of the
mean. Scale bar 5 100 lm.
Fig. 8. The schematic
summarizes the findings of
our study. Under basal con-
ditions, mice carrying K8
variants display normal liver
architecture and keratin fila-
ment network, but harbor
more keratin cross-links and
have lower NNMT levels than
animals overexpressing WT
K8. After APAP administra-
tion, mice with K8 variants
exhibit increased liver injury,
JNK activation (i.e., P-JNK)
APAP adducts formation, and
alterations in K8/K18 fila-
ment organization.
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epidermal K5/K14 when exposed to osmotic stress25 or
in mice ectopically expressing K10 in the basal epider-
mal layers.26 The increased formation of APAP protein
adducts also likely contributes to the increased APAP
hepatotoxicity observed in mice with K8 variants.
Though further studies are needed to determine the
exact underlying mechanisms, the decreased NNMT
levels in mutant keratin-expressing mice are likely to be
important.21,27 In that respect, our data demonstrated
an association between K8/K18 and NNMT; however,
the molecular domains involved in this association and
the impact of K8 variants on this process remain to be
characterized.
When challenged with APAP, mice overexpressing K8
variants displayed K8 hyperphosphorylation at S74 and
S432. The increased K8 pS74 levels are somewhat sur-
prising given that K8 G62C substitution blunts phos-
phorylation at this residue (by inducing a conformation
change28) in vitro using purified p38 kinase or in Tg K8
G62C that are exposed to Fas ligand.17,29 However, K8
S74 is phosphorylated by several kinases, including p38
kinase and JNK. Therefore, the inhibitory role of the
G62C substitution is likely restricted only to certain
kinases. Of note, JNK is also known to phosphorylate
K8 at S43229 and is therefore likely responsible, at least
in part, for the observed increase in K8 S432
hyperphosphorylation.
The increased K8 phosphorylation in mice with K8
variants likely accounts for the higher K8 solubility as
well as APAP-induced K8/K18 network reorganization,
thereby overcoming the impact of K8 G62C that would
otherwise be expected to decrease K8 solubility through
disulfide bond formation.16,17 Other post-translational
modifications might also be important given that some
of them affect keratin solubility as well.16
The more prominent disruption of pericentral keratin
filament network in animals with K8 variants represents
another factor likely contributing to the development of
APAP-induced liver injury. In that respect, keratins con-
stitute the major mechanical stabilizers of the cell,30 and
the cellular fragility resulting from keratin network dis-
ruption might be particularly detrimental in the case of
APAP-induced hepatocyte swelling.3,4,12 In agreement,
keratin network disruption has been linked to hepatocel-
lular ballooning in multiple liver disorders.31 Of note,
keratin network disruption has been associated with sus-
ceptibility to oxidative stress as well as with impaired
mitochondrial function that constitute important mech-
anisms promoting APAP toxicity.3,4,32,33
In contrast to APAP-mediated hepatotoxicity, the K8
variants did not affect the development of BDL-induced
liver injury or fibrosis. This finding further underscores
the previous observations showing that K8/K18 variant-
based predisposition to liver injury is context specific. In
that respect, K18 R90C mutation increases susceptibil-
ity to Fas-induced, but not TNF-a-induced, apoptosis
and liver damage, and to thioacetamide-mediated, but
not CCl4-mediated, fibrogenesis.
34,35 In humans, exonic
K8/K18 variants segregate with poor outcome or liver
disease progression in patients with ALF, PBC, or
chronic hepatitis C infection, but do not associate with
progression of hemochromatosis-induced liver
damage.6,22,36,37
In summary, our findings provide insight and support
for the disease relevance of human K8 variants in APAP-
associated liver injury.
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